Quinn Opportunity Partners LLC Purchases 4,940 Shares of Medifast Inc $MED

Quinn Opportunity Partners LLC increased its position in Medifast Inc (NYSE:MED) by 4.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 127,112 shares of the specialty retailer’s stock after acquiring an additional 4,940 shares during the period. Quinn Opportunity Partners LLC’s holdings in Medifast were worth $1,786,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of MED. Nisa Investment Advisors LLC grew its stake in shares of Medifast by 370.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,144 shares of the specialty retailer’s stock valued at $30,000 after purchasing an additional 1,688 shares during the period. Strs Ohio purchased a new stake in Medifast during the first quarter valued at approximately $78,000. CWM LLC raised its position in Medifast by 564.6% in the second quarter. CWM LLC now owns 7,457 shares of the specialty retailer’s stock worth $105,000 after acquiring an additional 6,335 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Medifast by 114.1% during the 1st quarter. Russell Investments Group Ltd. now owns 19,514 shares of the specialty retailer’s stock worth $267,000 after acquiring an additional 10,401 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new stake in shares of Medifast during the 2nd quarter valued at $307,000. Institutional investors own 95.51% of the company’s stock.

Medifast Stock Performance

Shares of NYSE MED opened at $11.64 on Wednesday. The company has a market cap of $127.94 million, a P/E ratio of 36.38 and a beta of 0.82. Medifast Inc has a 52-week low of $11.25 and a 52-week high of $21.98. The firm’s fifty day moving average is $13.26 and its two-hundred day moving average is $13.53.

Medifast (NYSE:MED) last issued its earnings results on Monday, November 3rd. The specialty retailer reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.20). The firm had revenue of $89.41 million during the quarter, compared to the consensus estimate of $84.10 million. Medifast had a return on equity of 2.00% and a net margin of 0.76%. Medifast has set its Q4 2025 guidance at -1.250–0.70 EPS. As a group, analysts forecast that Medifast Inc will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

MED has been the topic of several analyst reports. Wall Street Zen downgraded Medifast from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $16.50.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.